News

The primary efficacy endpoint is the proportion of subjects achieving at least a 50% improvement in the Facial Vitiligo Area Scoring Index.

Turn Therapeutics' Bradley Burnam recently spoke with Dermatology Times.

Click here to answer today's poll and read more about providing patients with multidisciplinary care.

This week’s collection of the latest dermatologic studies includes the use of digital communication for patients with hidradenitis suppurativa (HS), rituximab for pediatric patients with pemphigus, a case report of primary oral extramammary Paget disease, and the efficacy and safety of LAight therapy for HS.

Researchers found evidence from numerous studies claiming LDI could improve rosacea symptoms and decrease flare-ups.

These findings may provide guidance for future international definitions of degrees of activity and repigmentation in vitiligo.

Upadacitinib is now available as a tablet or an oral solution for patients 2 years and older with pJIA as well as PsA.

In a recent study, platelet-rich plasma not only increased hair regrowth but also rebalanced the scalp microbiome in patients with AGA.

With so many sessions and posters, there is a plethora of topics offered at this year's SDPA Summer Conference.

Zabinski, vice president and head of commercial strategy and AI at OM1, discusses the evolving role of AI in dermatology, focusing on its potential and challenges in skin cancer detection.

Phase 3 trials have been initiated in patients with high-risk melanoma.

The organization is highlighting stories and resources during Acne Awareness Month through the power of social media.

UCB recently announced phase 3 BE HEARD I and II trial results on bimekizumab for treating moderate to severe HS were published in The Lancet.

Catch up on a weekend full of clinical pearls from the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Dermatology Times asked our readers to share what conferences they are looking forward to in the second quarter of 2024.

Catch up on coverage from the last day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Jason Hawkes, MD, MS, detailed each of the kinases' association with different cytokine receptors and biological functions.

James Song, MD, explains combination treatment efficacy, addresses comorbidities, and provides pearls to improve patient safety.

Lockshin shared his approach to continuing biologic therapies into pregnancy with informed timing adjustments.

Jason Hawkes, MD, MS, breaks down boxed warning pros and cons and research addressing several boxed warnings.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Keep up with the latest headlines in dermatology from the past week, including US sunscreen versus global regulations, all-time high melanoma rates in the UK, and more.

Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.